Reckitt Benckiser Group (LON:RB) had its price objective raised by research analysts at Goldman Sachs Group from GBX 7,025 ($91.79) to GBX 7,090 ($92.64) in a research report issued on Tuesday. The brokerage currently has a “neutral” rating on the stock. Goldman Sachs Group’s price objective points to a potential upside of 11.57% from the company’s previous close.
Several other equities research analysts have also commented on RB. Barclays set a GBX 6,450 ($84.28) price target on shares of Reckitt Benckiser Group and gave the stock a “neutral” rating in a report on Friday, July 6th. Jefferies Financial Group set a GBX 6,660 ($87.02) price target on shares of Reckitt Benckiser Group and gave the stock a “neutral” rating in a report on Thursday, July 12th. JPMorgan Chase & Co. reissued a “buy” rating and issued a price target on shares of Reckitt Benckiser Group in a report on Monday, July 16th. BNP Paribas set a GBX 6,600 ($86.24) price target on shares of Reckitt Benckiser Group and gave the stock a “neutral” rating in a report on Monday, July 16th. Finally, Credit Suisse Group set a GBX 5,500 ($71.87) price target on shares of Reckitt Benckiser Group and gave the stock a “sell” rating in a report on Thursday, July 19th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the stock. Reckitt Benckiser Group has an average rating of “Hold” and a consensus price target of GBX 6,999.47 ($91.46).
LON:RB opened at GBX 6,355 ($83.04) on Tuesday. Reckitt Benckiser Group has a 1-year low of GBX 5,562 ($72.68) and a 1-year high of GBX 8,110.43 ($105.98).
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Featured Story: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.